UBS Group
DRUG

UBS Group’s Bright Minds Biosciences DRUG Stock Holding History

UBS Group’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$969K Sell
13,280
-533
-4% -$42.9K ﹤0.01% 5585
2025
Q4 		$1.08M Buy
13,813
+12,224
+769% +$817K ﹤0.01% 5496
2025
Q3 		$96.4K Sell
1,589
-325
-17% -$12.6K ﹤0.01% 7142
2025
Q2 		$50K Sell
1,914
-9,621
-83% -$288K ﹤0.01% 7774
2025
Q1 		$416K Buy
11,535
+1,374
+14% +$50.3K ﹤0.01% 5993
2024
Q4 		$366K Buy
10,161
+6,754
+198% +$238K ﹤0.01% 6059
2024
Q3 		$3.99K Buy
+3,407
New +$3.85K ﹤0.01% 8197
2024
Q1 		– Sell
-622
Closed -$889 – 9450
2023
Q4 		$889 Buy
+622
New +$888 ﹤0.01% 8483
2023
Q3 		– Sell
-420
Closed -$1.2K – 9563
2023
Q2 		$1.2K Sell
420
-1,760
-81% -$4.95K ﹤0.01% 7986
2023
Q1 		$4.8K Buy
2,180
+1,138
+109% +$3.77K ﹤0.01% 8143
2022
Q4 		$3.85K Sell
1,042
-1,925
-65% -$9.53K ﹤0.01% 9440
2022
Q3 		$18K Buy
2,967
+1,512
+104% +$9.8K ﹤0.01% 7514
2022
Q2 		$6K Buy
1,455
+765
+111% +$4.05K ﹤0.01% 8665
2022
Q1 		$5K Buy
690
+378
+121% +$4.24K ﹤0.01% 9109
2021
Q4 		$5K Buy
+312
New +$6.94K ﹤0.01% 9386

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

UBS Group's DRUG Position: Q1 2026 in Review

UBS Group reduced its Bright Minds Biosciences (DRUG) stake by 3.9% in Q1 2026, selling an estimated $42.9K and leaving 13,280 shares worth $969K. The position accounts for ﹤0.01% of the portfolio, ranked #5585.

UBS Group first reported a position in DRUG in Q4 2021 and has held it in 15 quarters since. The position peaked at $1.08M in Q4 2025. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • UBS Group held 13,280 shares of Bright Minds Biosciences worth $969K as of Q1 2026.
  • UBS Group sold 533 Bright Minds Biosciences shares in Q1 2026, an estimated $42.9K.
  • Bright Minds Biosciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5585 holding.
  • UBS Group first reported a position in Bright Minds Biosciences in Q4 2021 and has held it in 15 quarters since.
  • UBS Group's Bright Minds Biosciences position peaked at $1.08M in Q4 2025.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.